Cargando…

Regulation of pathological blood-brain barrier for intracranial enhanced drug delivery and anti-glioblastoma therapeutics

The blood-brain barrier (BBB) is an essential component in regulating and maintaining the homeostatic microenvironment of the central nervous system (CNS). During the occurrence and development of glioblastoma (GBM), BBB is pathologically destroyed with a marked increase in permeability. Due to the...

Descripción completa

Detalles Bibliográficos
Autores principales: WANG, KAI, ZHANG, FENGTIAN, WEN, CHANGLONG, HUANG, ZHIHUA, HU, ZHIHAO, ZHANG, YUWEN, HU, FUQIANG, WEN, LIJUAN
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tech Science Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208024/
https://www.ncbi.nlm.nih.gov/pubmed/37305160
http://dx.doi.org/10.32604/or.2022.025696
_version_ 1785046582412967936
author WANG, KAI
ZHANG, FENGTIAN
WEN, CHANGLONG
HUANG, ZHIHUA
HU, ZHIHAO
ZHANG, YUWEN
HU, FUQIANG
WEN, LIJUAN
author_facet WANG, KAI
ZHANG, FENGTIAN
WEN, CHANGLONG
HUANG, ZHIHUA
HU, ZHIHAO
ZHANG, YUWEN
HU, FUQIANG
WEN, LIJUAN
author_sort WANG, KAI
collection PubMed
description The blood-brain barrier (BBB) is an essential component in regulating and maintaining the homeostatic microenvironment of the central nervous system (CNS). During the occurrence and development of glioblastoma (GBM), BBB is pathologically destroyed with a marked increase in permeability. Due to the obstruction of the BBB, current strategies for GBM therapeutics still obtain a meager success rate and may lead to systemic toxicity. Moreover, chemotherapy could promote pathological BBB functional restoration, which results in significantly reduced intracerebral transport of therapeutic agents during multiple administrations of GBM and the eventual failure of GBM chemotherapy. The effective delivery of intracerebral drugs still faces severe challenges. However, strategies that regulate the pathological BBB to enhance the transport of therapeutic agents across the barrier may provide new opportunities for the effective and safe treatment of GBM. This article reviews the structure and function of BBB in physiological states, the mechanisms underlying BBB pathological fenestration during the development of GBM, and the therapeutic strategies of GBM based on BBB intervention and medicinal drugs transporting across the BBB.
format Online
Article
Text
id pubmed-10208024
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Tech Science Press
record_format MEDLINE/PubMed
spelling pubmed-102080242023-06-10 Regulation of pathological blood-brain barrier for intracranial enhanced drug delivery and anti-glioblastoma therapeutics WANG, KAI ZHANG, FENGTIAN WEN, CHANGLONG HUANG, ZHIHUA HU, ZHIHAO ZHANG, YUWEN HU, FUQIANG WEN, LIJUAN Oncol Res Review The blood-brain barrier (BBB) is an essential component in regulating and maintaining the homeostatic microenvironment of the central nervous system (CNS). During the occurrence and development of glioblastoma (GBM), BBB is pathologically destroyed with a marked increase in permeability. Due to the obstruction of the BBB, current strategies for GBM therapeutics still obtain a meager success rate and may lead to systemic toxicity. Moreover, chemotherapy could promote pathological BBB functional restoration, which results in significantly reduced intracerebral transport of therapeutic agents during multiple administrations of GBM and the eventual failure of GBM chemotherapy. The effective delivery of intracerebral drugs still faces severe challenges. However, strategies that regulate the pathological BBB to enhance the transport of therapeutic agents across the barrier may provide new opportunities for the effective and safe treatment of GBM. This article reviews the structure and function of BBB in physiological states, the mechanisms underlying BBB pathological fenestration during the development of GBM, and the therapeutic strategies of GBM based on BBB intervention and medicinal drugs transporting across the BBB. Tech Science Press 2022-10-10 /pmc/articles/PMC10208024/ /pubmed/37305160 http://dx.doi.org/10.32604/or.2022.025696 Text en © 2022 Wang et al. https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
WANG, KAI
ZHANG, FENGTIAN
WEN, CHANGLONG
HUANG, ZHIHUA
HU, ZHIHAO
ZHANG, YUWEN
HU, FUQIANG
WEN, LIJUAN
Regulation of pathological blood-brain barrier for intracranial enhanced drug delivery and anti-glioblastoma therapeutics
title Regulation of pathological blood-brain barrier for intracranial enhanced drug delivery and anti-glioblastoma therapeutics
title_full Regulation of pathological blood-brain barrier for intracranial enhanced drug delivery and anti-glioblastoma therapeutics
title_fullStr Regulation of pathological blood-brain barrier for intracranial enhanced drug delivery and anti-glioblastoma therapeutics
title_full_unstemmed Regulation of pathological blood-brain barrier for intracranial enhanced drug delivery and anti-glioblastoma therapeutics
title_short Regulation of pathological blood-brain barrier for intracranial enhanced drug delivery and anti-glioblastoma therapeutics
title_sort regulation of pathological blood-brain barrier for intracranial enhanced drug delivery and anti-glioblastoma therapeutics
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208024/
https://www.ncbi.nlm.nih.gov/pubmed/37305160
http://dx.doi.org/10.32604/or.2022.025696
work_keys_str_mv AT wangkai regulationofpathologicalbloodbrainbarrierforintracranialenhanceddrugdeliveryandantiglioblastomatherapeutics
AT zhangfengtian regulationofpathologicalbloodbrainbarrierforintracranialenhanceddrugdeliveryandantiglioblastomatherapeutics
AT wenchanglong regulationofpathologicalbloodbrainbarrierforintracranialenhanceddrugdeliveryandantiglioblastomatherapeutics
AT huangzhihua regulationofpathologicalbloodbrainbarrierforintracranialenhanceddrugdeliveryandantiglioblastomatherapeutics
AT huzhihao regulationofpathologicalbloodbrainbarrierforintracranialenhanceddrugdeliveryandantiglioblastomatherapeutics
AT zhangyuwen regulationofpathologicalbloodbrainbarrierforintracranialenhanceddrugdeliveryandantiglioblastomatherapeutics
AT hufuqiang regulationofpathologicalbloodbrainbarrierforintracranialenhanceddrugdeliveryandantiglioblastomatherapeutics
AT wenlijuan regulationofpathologicalbloodbrainbarrierforintracranialenhanceddrugdeliveryandantiglioblastomatherapeutics